Record Revenue Growth
Total revenues for the quarter were $18.9 million, a $4.7 million or 33% increase from the previous year's quarter. Year-to-date revenues were $37.7 million, a $14.5 million or 63% increase compared to the previous year.
Significant Profit Increase
Operating income was $3.5 million for the quarter and $7.3 million for the six months, representing an 81% increase quarter-to-quarter and a 108% increase year-to-date compared to last year.
Strong Cash Flow Position
Operating cash flow for the six months ended September 2024 was a positive $4.6 million, a $7.5 million turnaround from the previous year's negative $2.9 million.
Pipeline Expansion
New product launches included methotrexate and Codeine APAP, with upcoming launches of hydrocodone and APAP, Oxy/APAP, and methadone. A pending ANDA approval for a central nervous system product is expected soon.
Facility Expansion
A new 35,000 square foot packaging and warehouse facility has been completed, tripling existing warehouse space and quadrupling controlled substance vault capacity.